ALLO Quote, Financials, Valuation and Earnings

ANI Pharmaceuticals has a net margin of -295454.55% compared to Allogene Therapeutics's net margin of -16.29%. Allogene Therapeutics's return on equity of -52.73% beat ANI Pharmaceuticals's return on equity of -1.54%.

Allogene Therapeutics has a consensus price target of $9.23, signalling upside risk potential of 292.65%. On the other hand ANI Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 45.25%. Given that Allogene Therapeutics has higher upside potential than ANI Pharmaceuticals, analysts believe Allogene Therapeutics is more attractive than ANI Pharmaceuticals.

Allogene Therapeutics has a beta of 0.855, which suggesting that the stock is 14.457% less volatile than S&P 500. In comparison ANI Pharmaceuticals has a beta of 0.733, suggesting its less volatile than the S&P 500 by 26.67%.

Allogene Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics pays -- of its earnings as a dividend. ANI Pharmaceuticals pays out 8.65% of its earnings as a dividend. ANI Pharmaceuticals's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Allogene Therapeutics quarterly revenues are $22K, which are smaller than ANI Pharmaceuticals quarterly revenues of $148.3M. Allogene Therapeutics's net income of -$66.3M is lower than ANI Pharmaceuticals's net income of -$24.2M. Notably, Allogene Therapeutics's price-to-earnings ratio is -- while ANI Pharmaceuticals's PE ratio is 55.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics is 4,975.57x versus 1.89x for ANI Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Armata Pharmaceuticals has a net margin of -295454.55% compared to Allogene Therapeutics's net margin of --. Allogene Therapeutics's return on equity of -52.73% beat Armata Pharmaceuticals's return on equity of --.

Allogene Therapeutics has a consensus price target of $9.23, signalling upside risk potential of 292.65%. On the other hand Armata Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 238.16%. Given that Allogene Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Allogene Therapeutics is more attractive than Armata Pharmaceuticals.

Allogene Therapeutics has a beta of 0.855, which suggesting that the stock is 14.457% less volatile than S&P 500. In comparison Armata Pharmaceuticals has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.895%.

Allogene Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics pays -- of its earnings as a dividend. Armata Pharmaceuticals pays out -- of its earnings as a dividend.

Allogene Therapeutics quarterly revenues are $22K, which are larger than Armata Pharmaceuticals quarterly revenues of --. Allogene Therapeutics's net income of -$66.3M is lower than Armata Pharmaceuticals's net income of -$5.5M. Notably, Allogene Therapeutics's price-to-earnings ratio is -- while Armata Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics is 4,975.57x versus 749.94x for Armata Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics has a net margin of -295454.55% compared to Allogene Therapeutics's net margin of --. Allogene Therapeutics's return on equity of -52.73% beat Perspective Therapeutics's return on equity of --.

Allogene Therapeutics has a consensus price target of $9.23, signalling upside risk potential of 292.65%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that Perspective Therapeutics has higher upside potential than Allogene Therapeutics, analysts believe Perspective Therapeutics is more attractive than Allogene Therapeutics.

Allogene Therapeutics has a beta of 0.855, which suggesting that the stock is 14.457% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Allogene Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Allogene Therapeutics quarterly revenues are $22K, which are larger than Perspective Therapeutics quarterly revenues of --. Allogene Therapeutics's net income of -$66.3M is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Allogene Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics is 4,975.57x versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -295454.55% compared to Allogene Therapeutics's net margin of 18.02%. Allogene Therapeutics's return on equity of -52.73% beat Protalix BioTherapeutics's return on equity of -29.54%.

Allogene Therapeutics has a consensus price target of $9.23, signalling upside risk potential of 292.65%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 516.74%. Given that Protalix BioTherapeutics has higher upside potential than Allogene Therapeutics, analysts believe Protalix BioTherapeutics is more attractive than Allogene Therapeutics.

Allogene Therapeutics has a beta of 0.855, which suggesting that the stock is 14.457% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

Allogene Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Allogene Therapeutics pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Allogene Therapeutics quarterly revenues are $22K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Allogene Therapeutics's net income of -$66.3M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Allogene Therapeutics's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Allogene Therapeutics is 4,975.57x versus 3.90x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.